Lymphoma Hub

De: Scientific Education Support
Escúchala gratis

  • Resumen

  • The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

    Hosted on Acast. See acast.com/privacy for more information.
    Scientific Education Support
    Más Menos
Más Menos
Episodios
  • inMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL

    inMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL
    Apr 1 2025

    During the 66th American Society of Hematology (ASH) Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari, University of Modena and Reggio Emilia, Modena, IT. We asked about the latest updates from the inMIND trial of tafasitamab plus lenalidomide and rituximab for R/R FL.

    In this interview, Luminari shares data from the phase III inMIND (NCT04680052) trial of patients with relapsed/refractory follicular lymphoma treated with tafasitamab in combination with lenalidomide and rituximab. Luminari covers key outcomes, highlighting promising efficacy and safety data. He concludes that the data are encouraging and supports using this combination for patients with relapsed/refractory follicular lymphoma in the second-line setting.


    This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
    6 m
  • Symposium | Optimizing outcomes before and after CAR T-cell therapy in patients with large B-cell lymphoma

    Symposium | Optimizing outcomes before and after CAR T-cell therapy in patients with large B-cell lymphoma
    Aug 12 2024
    During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled: Sequencing immune-based therapies in B-cell malignancies. Here, the Lymphoma Hub is pleased to share a real-world patient case, real-world evidence and experience, and treatment optimization of chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma (LBCL), presented by Ulrich Jäger, Medical University of Vienna, Vienna, AT.

    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
    27 m
  • SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL

    SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL
    Aug 12 2024

    During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest updates from the SEQUOIA trial of zanubrutinib + venetoclax in treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).


    In this interview, Paolo Ghia shares data from Arm D of the phase III SEQUOIA (NCT03336333) study of patients with del(17p) and/or pathogenic TP53 mutation treated with zanubrutinib in combination with venetoclax. Ghia covers key preliminary outcomes, highlighting promising remission data and an increased depth of response measured over time. This interview concludes with a look at the future implications of these data, particularly on measurable residual disease-guided treatment cessation.


    This educational resource is independently supported by BeiGene. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
    5 m
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre Lymphoma Hub

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles